PR Newswire·Oct 9, 2025, 7:05 AM ET

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting

REGENXBIO Inc. will present interim 2-year data from the Phase II ALTITUDE trial for surabgene lomparvovec (sura-vec) at the American Academy of Ophthalmology 2025 Annual Meeting.
The presentation on non-proliferative diabetic retinopathy is scheduled for October 17 at 4:46 p.m. ET, delivered by Charles C. Wykoff, M.D., PhD.
Sura-vec is an investigational one-time gene therapy developed in collaboration with AbbVie, designed as a potential first-in-class treatment for wet AMD and diabetic retinopathy.
The therapy utilizes the NAV AAV8 vector to encode an antibody fragment that inhibits the VEGF pathway to prevent new leaky blood vessel growth.
REGENXBIO maintains a late-stage pipeline including RGX-202 for Duchenne muscular dystrophy, clemidsogene lanparvovec for MPS II, and RGX-111 for MPS I.
Thousands of patients have been treated using REGENXBIO's AAV platform, including recipients of Novartis' ZOLGENSMA.
The press release includes standard forward-looking statements regarding future clinical trial outcomes, regulatory approvals, & potential market acceptance.